Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on ...

Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: BHP Billiton (BHP) 14.94% +4.96, Bitfarms ...

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares opened ...

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They ...

(RTTNews) - Lexicon Pharmaceuticals, Inc. (LXRX) is scheduled to report topline results from its Phase 2b PROGRESS study evaluating Pilavapadin or LX9211, an oral, non-opioid investigational ...

Shares of Lexicon Pharmaceuticals , Inc. (Nasdaq: NASDAQ: LXRX) plummeted 50% following the announcement of topline results from its Phase 2b PROGRESS study, which evaluated the efficacy of ...

Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the ...

Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) tumbled 55% after the company announced topline results from its PROGRESS Phase 2b study, which evaluated pilavapadin in ...